Wallar Gina M 4
4 · NEOGENOMICS INC · Filed Jul 7, 2021
Insider Transaction Report
Form 4
Wallar Gina M
President, Pharma Services
Transactions
- Award
Stock Option (Right to Buy)
2021-07-05$43.95/sh+10,126$445,038→ 10,126 totalExercise: $43.95Exp: 2028-07-05→ Common Stock (10,126 underlying) - Award
Common Stock
2021-07-05+1,896→ 6,013 total
Holdings
- 7,879
Stock Option (Right to Buy)
Exercise: $27.34Exp: 2027-05-01→ Common Stock (7,879 underlying) - 6,667
Stock Option (Right to Buy)
Exercise: $9.22Exp: 2023-04-19→ Common Stock (6,667 underlying) - 8,334
Stock Option (Right to Buy)
Exercise: $13.87Exp: 2023-12-12→ Common Stock (8,334 underlying) - 7,153
Stock Option (Right to Buy)
Exercise: $20.83Exp: 2026-05-01→ Common Stock (7,153 underlying) - 8,595
Stock Option (Right to Buy)
Exercise: $48.99Exp: 2028-05-01→ Common Stock (8,595 underlying)
Footnotes (6)
- [F1]On April 19, 2018, Ms. Wallar was granted 20,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.
- [F2]On December 12, 2018, Ms. Wallar was granted 25,000 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- [F3]On May 1, 2019, Ms. Wallar was granted 9,537 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- [F4]On May 1, 2020, Ms. Wallar was granted 7,879 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- [F5]On May 1, 2021, Ms. Wallar was granted 8,595 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- [F6]On July 5, 2021, Ms. Wallar was granted 10,126 stock options. The options vest ratably over the first four anniversary dates of the grant date.